Despite accounts of mutual exclusivity observed in primary tumors, our genetic mouse model experiments indicate co-existing TP53 and ARID1A mutations are tolerated in vivo and promote more aggressive cancer phenotypes than either mutation independently. The gene discussed is ARID1A; the disease is cancer.